Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
A Long-Term Follow-Up Study of Subjects With Fabry Disease Who Previously Received Ex-Vivo, Lentiviral Vector-Mediated Gene-Modified Autologous Cell Therapy AVR-RD-01 in Study AVRO-RD-01-201
Sponsor: AVROBIO
Terminated
This study was voluntarily terminated due to a business decision not to proceed, and not due to any safety or efficacy issue.
Other terminated trials from AVROBIO
- Gaucher Disease · Phase PHASE1/PHASE2 · Aug 2023
- Type 1 Gaucher Disease · Aug 2023
- Fabry Disease · Phase PHASE1/PHASE2 · Mar 2022
More terminations from AVROBIO
Other Fabry Disease trials with similar outcome
This observational or N/A phase trial investigates Fabry Disease and is currently terminated or withdrawn. AVROBIO leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Sep 2023 — Jul 2024 [monthly]
Terminated
Status: Enrolling By Invitation → Terminated
-
Nov 2022 — Sep 2023 [monthly]
Enrolling By Invitation
-
Jan 2022 — Nov 2022 [monthly]
Enrolling By Invitation
▶ Show 2 earlier versions
-
Dec 2021 — Jan 2022 [monthly]
Enrolling By Invitation
-
Sep 2021 — Dec 2021 [monthly]
Enrolling By Invitation
First recorded
May 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AVROBIO
For direct contact, visit the study record on ClinicalTrials.gov .